These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15886157)

  • 1. Vaccine advance-purchase agreements for low-income countries: practical issues.
    Berndt ER; Hurvitz JA
    Health Aff (Millwood); 2005; 24(3):653-65. PubMed ID: 15886157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of globalization on vaccine development and availability.
    Milstien JB; Kaddar M; Kieny MP
    Health Aff (Millwood); 2006; 25(4):1061-9. PubMed ID: 16835187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines as a global imperative--a business perspective.
    Stéphenne J
    Health Aff (Millwood); 2011 Jun; 30(6):1042-8. PubMed ID: 21653955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The problems and promise of vaccine markets in developing countries.
    Batson A
    Health Aff (Millwood); 2005; 24(3):690-3. PubMed ID: 15886160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global perspectives on vaccine financing.
    Berman S; Giffin RB
    Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.
    Jadhav S; Datla M; Kreeftenberg H; Hendriks J
    Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Influenza vaccine: globalization of public health stakes].
    Collin N; Briand S
    Med Trop (Mars); 2009 Aug; 69(4):322. PubMed ID: 19725377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness.
    Berndt ER; Glennerster R; Kremer MR; Lee J; Levine R; Weizsäcker G; Williams H
    Health Econ; 2007 May; 16(5):491-511. PubMed ID: 17013993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming economic barriers to the optimal use of vaccines.
    Lieu TA; McGuire TG; Hinman AR
    Health Aff (Millwood); 2005; 24(3):666-79. PubMed ID: 15886158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Market-based licensing for HPV vaccines in developing countries.
    Outterson K; Kesselheim AS
    Health Aff (Millwood); 2008; 27(1):130-9. PubMed ID: 18180488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introducing new vaccines into developing countries: obstacles, opportunities and complexities.
    Clemens J; Jodar L
    Nat Med; 2005 Apr; 11(4 Suppl):S12-5. PubMed ID: 15812482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paving the way for the introduction of new vaccines into developing countries.
    Chabalgoity JA
    Expert Rev Vaccines; 2005 Apr; 4(2):147-50. PubMed ID: 15889986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries.
    Batson A; Meheus F; Brooke S
    Vaccine; 2006 Aug; 24 Suppl 3():S3/219-25. PubMed ID: 16950010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why certain vaccines have been delayed or not developed at all.
    Plotkin SA
    Health Aff (Millwood); 2005; 24(3):631-4. PubMed ID: 15886153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting U.S. manufacturers' decisions to produce vaccines.
    Coleman MS; Sangrujee N; Zhou F; Chu S
    Health Aff (Millwood); 2005; 24(3):635-42. PubMed ID: 15886154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine shortages: history, impact, and prospects for the future.
    Hinman AR; Orenstein WA; Santoli JM; Rodewald LE; Cochi SL
    Annu Rev Public Health; 2006; 27():235-59. PubMed ID: 16533116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine supply: a cross-national perspective.
    Danzon PM; Pereira NS; Tejwani SS
    Health Aff (Millwood); 2005; 24(3):706-17. PubMed ID: 15886165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced purchase commitments for a malaria vaccine.
    Natl Bur Econ Res Bull Aging Health; 2005; (12):1-2. PubMed ID: 16175672
    [No Abstract]   [Full Text] [Related]  

  • 20. The GO License: only part of the solution.
    Batson A; Milstien JB
    Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.